--(BUSINESS WIRE)--Arterial Remodeling Technologies (“ART”) is developing a bioresorbable polymer stent that promotes the natural remodeling of an injured artery after angioplasty. The Company’s technology is based on intellectual property originating from three esteemed institutions: the Cleveland Clinic (Cleveland, Ohio); the French national research institute, C.N.R.S. (Centre National de Recherche Scientifique), Montpellier, France; and, Necker University, Paris. ART’s bioresorbable stent is designed to dismantle in vivo over an optimized time horizon, thus allowing the body’s own natural arterial remodeling process to occur, unrestricted by the presence of a permanent metallic stent.
|
Company: |
Arterial Remodeling Technologies | |
|
Headquarters Address: |
3, rue de Verdun - Bât.G | |
| Noisly le Roi 78590 | ||
| France | ||
|
Main Telephone: |
+33 (0)1 61 06 19 92 | |
|
Website: |
||
|
Type of Organization: |
Private | |
| PR | ||
|
Industry: |
Medical Devices | |
|
Key Executives: |
CEO: Machiel van der Leest |
|
|
Public Relations |
||
|
Contact: |
Ronald Trahan | |
|
Phone: |
5083594005 | |
|
Email: |
